The US Food and Drug Administration has bowed to calls that it do away with the requirement that the abortion pill Mifeprex (mifepristone) be dispensed to patients at a hospital, clinic, or medical office.
In response to a lawsuit filed by the American Civil Liberties Union, the agency reviewed its Risk Evaluation and Mitigation Strategy (REMS) for Mifeprex
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?